EVOLUS, INC. (EOLS) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$2.21M; Operating income (m); Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA -$4.5M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA $6.47M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$9.55M; Operating income (m); Depreciation and amortization (m).
Complete source-backed ebitda history.
- Available history
- 2017-03-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$2.21M | (m) | (m) | $84.08M | -2.62% | $50.00K* | -$3.59M* | $26.90M | (m) | $57.05M | -$154.00K |
|---|
| 2026-03-31 | Reported | -$4.5M | (m) | (m) | $73.14M | -6.16% | $415.00K | -$9.95M | $24.24M | (m) | $51.98M | $256.00K |
|---|
| 2025-12-31 | Reported | $6.47M | (m) | (m) | $90.3M | 7.17% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$9.55M | (m) | (m) | $68.97M | -13.85% | $955.00K* | -$14.67M* | $23.13M | (m) | $52.82M | $167.00K |
|---|
| 2025-06-30 | Reported | -$8.47M | (m) | (m) | $69.39M | -12.21% | $688.00K* | -$24.79M* | $24.07M | (m) | $56.67M | $53.00K |
|---|
| 2025-03-31 | Reported | -$13.61M | (m) | (m) | $68.52M | -19.86% | $319.00K | -$15.63M | $21.87M | (m) | $56.64M | $72.00K |
|---|
| 2024-12-31 | Reported | -$940,000.00 | (m) | (m) | $78.95M | -1.19% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$14.39M | (m) | (m) | $61.09M | -23.55% | $313.00K* | -$5.72M* | $18.99M | (m) | $52.51M | $134.00K |
|---|
| 2024-06-30 | Reported | -$6.28M | (m) | (m) | $66.91M | -9.38% | $465.00K* | -$6.47M* | $19.84M | (m) | $50.15M | $43.00K |
|---|
| 2024-03-31 | Reported | -$7.51M | (m) | (m) | $59.33M | -12.66% | $256.00K | -$10.62M | $18.83M | (m) | $45.12M | $47.00K |
|---|
| 2023-12-31 | Reported | -$7.26M | (m) | (m) | $61M | -11.91% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$12.13M | (m) | (m) | $50.02M | -24.25% | $29.00K* | -$924.00K* | $15.43M | (m) | $43.33M | $24.00K |
|---|
| 2023-06-30 | Reported | -$13.87M | (m) | (m) | $49.35M | -28.11% | $8.00K* | -$13.31M* | $14.71M | (m) | $41.17M | $23.00K |
|---|
| 2023-03-31 | Reported | -$10.84M | (m) | (m) | $41.72M | -25.98% | $227.00K | -$20.59M | $12.15M | (m) | $37.38M | $23.00K |
|---|
| 2022-12-31 | Reported | -$9.61M | (m) | (m) | $43.65M | -22.02% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2022-09-30 | Reported | -$16.98M | (m) | (m) | $33.9M | -50.08% | $509.00K* | -$17.05M* | $13.49M | (m) | $34.79M | $12.00K |
|---|
| 2022-06-30 | Reported | -$20.5M | (m) | (m) | $37.16M | -55.15% | $231.00K* | -$20.89M* | $15.82M | (m) | $36.88M | $28.00K |
|---|
| 2022-03-31 | Reported | -$14.53M | (m) | (m) | $33.91M | -42.84% | $12.00K | -$38.20M | $13.21M | $468.00K | $33.44M | -$2.00K |
|---|
| 2021-12-31 | Reported | -$17.11M | (m) | (m) | $34.66M | -49.36% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2021-09-30 | Reported | -$18.19M | (m) | (m) | $26.68M | -68.17% | $0.00* | -$32.13M* | $11.49M | $301.00K | $31.67M | $12.00K |
|---|
| 2021-06-30 | Reported | -$13.55M | (m) | (m) | $26.1M | -51.91% | $0.00* | $16.12M* | $11.30M | $499.00K | $26.46M | $9.00K |
|---|
| 2021-03-31 | Reported | $10.06M | (m) | (m) | $12.24M | 82.17% | $0.00 | -$8.34M | $4.91M | $841.00K | $20.66M | $12.00K |
|---|
| 2020-12-31 | Reported | -$106.15M | (m) | (m) | $20.58M | -515.87% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2020-09-30 | Reported | -$7.02M | (m) | (m) | $17.66M | -39.73% | $121.00K* | -$13.71M* | $4.85M | $350.00K | $21.94M | -$27.00K |
|---|
| 2020-06-30 | Reported | -$17.23M | (m) | (m) | $7.81M | -220.71% | $112.00K* | -$13.95M* | $1.95M | $145.00K | $17.55M | -$2.00K |
|---|
| 2020-03-31 | Reported | -$15.65M | (m) | (m) | $10.5M | -149.07% | $565.00K | -$27.95M | $4.22M | $507.00K | $31.30M | $256.00K |
|---|
| 2019-12-31 | Reported | -$11.08M | (m) | (m) | $19.45M | -56.95% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2019-09-30 | Reported | -$23.94M | (m) | (m) | $13.17M | -181.79% | $0.00* | -$25.10M* | $3.72M | $693.00K | $30.90M | -$149.00K |
|---|
| 2019-06-30 | Reported | -$35.02M | (m) | (m) | $2.31M | -1515.32% | $346.00K* | -$33.16M* | $660.00K | $509.00K | $34.89M | -$227.00K |
|---|
| 2019-03-31 | Reported | -$24.79M | (m) | (m) | (m) | (m) | $0.00 | -$19.20M | $0.00 | $2.35M | $17.52M | -$14.52M |
|---|
| 2018-12-31 | Reported | -$12.51M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2018-09-30 | Reported | -$11.49M | (m) | (m) | (m) | (m) | $0.00* | -$5.80M* | $0.00 | $1.98M | $7.21M | $19.00K |
|---|
| 2018-06-30 | Reported | -$16.10M* | -$16.10M | $4.00K* | $0.00 | (m) | (m) | -$5.66M* | $0.00 | $1.65M | $6.25M | $12.00K |
|---|
| 2018-03-31 | Reported | -$6.05M | (m) | (m) | (m) | (m) | (m) | -$2.20M | (m) | $1.68M | (m) | $10.00K |
|---|
| 2017-12-31 | Reported | -$2.86M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2017-09-30 | Reported | -$2.62M* | -$2.62M | $0.00* | (m) | (m) | $0.00* | -$3.43M* | (m) | $1.47M | (m) | $16.00K |
|---|
| 2017-06-30 | Reported | -$2.17M* | -$2.27M | $107.00K* | (m) | (m) | (m) | -$3.21M* | (m) | $1.36M | (m) | $20.00K |
|---|
| 2017-03-31 | Reported | -$3.87M | (m) | (m) | (m) | (m) | (m) | -$5.58M | (m) | $2.65M | (m) | $20.00K |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$25.16M | (m) | (m) | $297.18M | -8.47% | $3.44M | -$42.27M | $100.07M | (m) | $220.79M | $677.00K |
|---|
| 2024-12-31 | Reported | -$29.11M | (m) | (m) | $266.27M | -10.93% | $1.47M | -$18.00M | $83.97M | (m) | $198.03M | $664.00K |
|---|
| 2023-12-31 | Reported | -$44.1M | (m) | (m) | $202.09M | -21.82% | $473.00K | -$34.01M | $64.51M | (m) | $164.94M | $176.00K |
|---|
| 2022-12-31 | Reported | -$61.61M | (m) | (m) | $148.62M | -41.45% | $1.62M | -$84.91M | $58.84M | (m) | $141.84M | $95.00K |
|---|
| 2021-12-31 | Reported | -$38.78M | (m) | (m) | $99.67M | -38.91% | $393.00K | -$33.39M | $43.53M | $2.06M | $112.07M | $42.00K |
|---|
| 2020-12-31 | Reported | -$146.04M | (m) | (m) | $56.54M | -258.30% | $815.00K | -$57.87M | $18.30M | $1.72M | $98.19M | $77.00K |
|---|
| 2019-12-31 | Reported | -$94.82M | (m) | (m) | $34.93M | -271.48% | $345.00K | -$93.38M | $8.01M | $3.97M | $113.59M | -$15.03M |
|---|
| 2018-12-31 | Reported | -$46.13M | (m) | (m) | (m) | (m) | $9.00K | -$25.67M | $0.00 | $6.49M | $29.15M | $65.00K |
|---|
| 2017-12-31 | Reported | -$11.51M | (m) | (m) | (m) | (m) | $0.00 | -$13.22M | (m) | $6.69M | (m) | -$7.25M |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
|---|
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
|---|
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
|---|